Recombinant Human LRIG3 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human LRIG3 Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit proliferation of HeLa human cervical epithelial carcinoma cells. Goldoni, S. et al. (2007) Oncogene, 26:368. The ED₅₀ for this effect is 1.5-6 µg/mL.
• Source: Mouse myeloma cell line, NS0-derived human LRIG3 protein
  Asp28-Thr807, with a C-terminal 6-His tag
• Accession #: Q6UXM1
• N-terminal Sequence: Asp28
• Protein/Peptide Type: Recombinant Proteins
• Gene: LRIG3
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 87.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 105-115 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 250 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human LRIG3 Protein, CF

• FLJ90440
• KIAA3016
• leucine-rich repeats and immunoglobulin-like domains 3
• leucine-rich repeats and immunoglobulin-like domains protein 3
• LIG-3
• LIG3FLJ26573
• LIRG3
• LRIG3

Background

LRIG3 (leucine-rich repeats and Ig-like domains-3) is a 140 kDa type I transmembrane glycoprotein member of the mammalian LRIG glycoprotein family. This family contains three members who share 45 - 50% amino acid (aa) identity (1). All members contain at least fifteen LRRs, accompanied by two flanking cysteine-rich regions, and three C2-type Ig-like domains in their extracellular domains (ECD) (1). LRIG3 mRNA is widely expressed, with highest levels in stomach, skin, thyroid and small intestine (1). Human LRIG3 is synthesized as a 1120 amino acid (aa) precursor. It contains a 24 aa signal sequence, a 786 aa ECD, a 21 aa transmembrane sequence, and a 289 aa intracellular region. One splice variant exists that has a 19 aa substitution for the first 79 aa of the standard (or long) form. This substitution appears to encode an alternate signal sequence, resulting in a mature protein that lacks the first and part of the second LRR. LRIG1, a related family member, is known to bind the EGF family receptors ErbB1-4, via either its LRR or Ig-like domains. It also binds the ubiquitin ligase, c-Cbl, and promotes ubiquitination, internalization and destruction of these receptors (2, 3). It is not known whether LRIG3 performs similar functions. Within the cell, LRIG3 is expressed in the perinuclear region as well as on the cell surface. Perinuclear location of LRIG3 in grade III and IV astrocytic tumors has been associated with better patient survival (4). Human LRIG3 ECD shows 91%, 92%, 95% and 98% aa identity with mouse, rat, bovine and canine LRIG3 ECD, respectively.

1. Guo, D. et al. (2004) Genomics 84:157.
2. Gur, G. et al. (2004) EMBO J. 23:3270.
3. Laederich, M.B. (2004) J. Biol. Chem. 279:47050.
4. Guo, D. et al. (2006) Acta Neuropathol. (Berl.) 111:238.

Bioinformatics

• Gene Symbol: LRIG3
• Uniprot:
  • Q6UXM1()